CryoPort (NASDAQ:CYRX) Insider Mark Sawicki Sells 1,341 Shares of Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Mark Sawicki sold 1,341 shares of CryoPort stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $8.18, for a total value of $10,969.38. Following the sale, the insider directly owned 102,356 shares of the company’s stock, valued at approximately $837,272.08. The trade was a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

CryoPort Price Performance

Shares of CYRX stock opened at $8.41 on Thursday. CryoPort, Inc. has a fifty-two week low of $4.63 and a fifty-two week high of $11.45. The stock’s 50-day moving average is $8.90 and its two-hundred day moving average is $9.32. The firm has a market cap of $419.32 million, a P/E ratio of 6.37 and a beta of 1.69.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. As a group, research analysts expect that CryoPort, Inc. will post -0.99 EPS for the current year.

Institutional Trading of CryoPort

A number of institutional investors and hedge funds have recently modified their holdings of the company. Basepoint Wealth LLC bought a new stake in shares of CryoPort during the 4th quarter worth $34,000. Tower Research Capital LLC TRC raised its holdings in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares during the period. Whittier Trust Co. of Nevada Inc. acquired a new position in CryoPort during the 3rd quarter worth $53,000. ProShare Advisors LLC acquired a new position in CryoPort during the 2nd quarter worth $75,000. Finally, AlphaQuest LLC bought a new stake in CryoPort during the third quarter valued at about $79,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CYRX. Wall Street Zen lowered shares of CryoPort from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Finally, Needham & Company LLC increased their target price on shares of CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $12.94.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.